<DOC>
	<DOCNO>NCT00424255</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled , multicentre , global Phase III trial compare efficacy adjuvant oral lapatinib versus placebo high-risk subject head neck cancer follow surgery . Lapatinib placebo administer post-operatively combination chemoradiotherapy follow maintenance lapatinib placebo 1 year . The primary goal determine lapatinib effective reduce recurrence disease high-risk patient .</brief_summary>
	<brief_title>Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery</brief_title>
	<detailed_description>A Randomised , Double-Blind , Placebo-Controlled , Multi-centre , Phase III Study Post-Operative Adjuvant Lapatinib Placebo Concurrent Chemoradiotherapy Followed Maintenance Lapatinib Placebo Monotherapy High-Risk Subjects Resected Squamous Cell Carcinoma Head Neck ( SCCHN )</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Willing able sign write informed consent . Histologically confirm diagnosis SCCHN one follow site : oral cavity , oropharynx , hypopharynx larynx . Pathological Stage II , III IVa ( accord AJCC cancer stag criterion [ Green , 2002 ] ) evidence gross residual disease , least one follow high risk factor pathology : Extracapsular extension nodal disease Positive resection margin ( 5 mm less ) Primary surgery curative intent complete within 46 week ( later 7 week ) prior randomization . The extent surgical resection follow accept criterion adequate excision [ Helliwell , 2005 ] . Surgical margin divide 'mucosal ' 'deep ' , category resection margin ( R ) classify : Clear : ( R0 ) &gt; 5mm . Close : ( R1 ) 1 5mm . Involved : ( R2 ) &lt; 1mm Complete recovery surgical procedure allow appropriate radiotherapy . Radiation therapy require start soon adequate healing occur . This normally around 46 week later 9 week surgery . Adequate tumour specimen archive resected tissue must available IHC evaluation ErbB1 expression level central laboratory subsequent biomarker analysis . Male female , 18 70 year age [ Bourhis , 2006 ] . Criteria female subject female partner male subject : Nonchildbearing potential ( i.e. , woman function ovary current document tubal ligation hysterectomy woman menopausal ) ; Childbearing potential ( i.e . woman function ovary document impairment oviductal uterine function would cause sterility . This category include woman oligomenorrhoea ( even severe ) , woman perimenopausal young woman begin menstruate ) , negative serum pregnancy test screening , agree one following : Complete abstinence intercourse time screen pregnancy test 28 day final dose test article ; Consistent correct use one follow acceptable method birth control : Male partner sterile prior female subject 's entry study sole sexual partner female subject ; Oral contraceptive ( either combine progestogen ) , Injectable progestogenonly contraceptives Implants levonorgestrel , Any intrauterine device document failure rate le 1 % per year ; Barrier method ( e.g . condom , diaphragm , cap ) use combination one acceptable method . ECOG performance status 0 , 1 2 Adequate haematology , renal hepatic function Absolute neutrophil count ≥ 1,500/μL , platelet ≥ 100,000/μL Haemoglobin ≥ 9 gm/dL ( 5mmol/L ) Calculated creatinine clearance ≥60 ml/min determine modify method Cockcroft Gault . Aspartate ( AST ) alanine transaminase ( ALT ) less 3 time upper limit normal range ( ULN ) . Total bilirubin ≤ 2.0 mg/dL Left ventricular ejection fraction ( LVEF ) low limit institutional normal range measure ECHO ( ECHO perform Investigator feel conclusive evaluate LVEF , MUGA scan perform ) . Able swallow retain tablet whole swallow suspension tablet dissolve water study inclusion . The use feed tube optional . If necessary , suspension may administer via percutaneous endoscopic gastrostomy ( PEG ) , percutaneous jejunostomy tube ( J Tube ) , nasogastric tube ( NG Dobhoff type tube ) . Life expectancy least 6 month best judgement investigator Current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , stable chronic liver disease per investigator assessment ) . Nasopharyngeal , paranasal sinus nasal cavity tumour Head neck cancer histology squamous cell carcinoma . Evidence distant metastasis gross postoperative residual disease . Evidence second primary tumour . Any prior current anticancer treatment kind except primary surgical resection . This include limit : prior tyrosine kinase inhibitor , prior neoadjuvant therapy , prior radiotherapy use investigational agent . Concurrent treatment investigational agent participation another clinical trial . Concurrent use CYP3A4 inducer inhibitor lapatinib/placebo . A standard 3 5 day course dexamethasone prevention cisplatin induce nausea vomiting permit . In addition glucocorticoid daily dos ( oral ) 1.5mg dexamethasone ( equivalent ) allow . Subjects know history uncontrolled symptomatic angina , arrhythmia , congestive heart failure ; Pregnant lactate female History another malignancy within last 5 year , exception completely resect basal squamous cell skin cancer , successfully treat insitu carcinoma . History noninvasive lesion insitu carcinoma , successfully treat surgery , photodynamics laser , permit ; Peripheral neuropathy ≥ grade 2 Malabsorption syndrome , disease significantly affect GI function , major resection stomach bowel , could affect absorption lapatinib . History allergic reaction relevant diuretic antiemetic ( e.g 5HT3 antagonist ) administer cisplatin chemotherapy History allergic reaction attribute compound similar chemical composition ( quinazolines ) lapatinib The investigator considers subject unfit study result medical interview , physical examination , screen investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cancer Head Neck</keyword>
	<keyword>Neck cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>High-risk head neck cancer</keyword>
	<keyword>Post-surgery</keyword>
	<keyword>Head cancer</keyword>
</DOC>